Inlab - Investigação Laboratorial Ltda. Acquisition

Fleury S.A. ("Fleury" or "Company"), pursuant to paragraph 4 of article 157 of Law 6,404/76 and CVM Instruction 358/02, informs its shareholders and the market in general that, on November 28th, 2019, has entered into a Sales and Purchase Agreement and Other Covenants and acquired 100% of the common stock of Inlab - Investigação Laboratorial Ltda. ("Inlab").

Inlab offers clinical analysis tests through 21 Patient Service Centers and a Central Lab in the metropolitan region of São Luís, State of Maranhão. Inlab estimated Gross Revenue, for the last 12 months ended in September 2019, reached R$ 39.9 million.

This acquisition marks the entry of Grupo Fleury in the State of Maranhão, representing another strategic movement of the Company, increasing its national capillarity and strengthening its portfolio in the northeast region of the country.

The acquisition amount of Inlab totaled R$ 90 million before deductions and adjustments.

Pursuant to Article 256 of Law No. 6,404/76, the acquisition of Inlab does not constitute a material investment and does not require the resolution of the Company‘s shareholders, nor will it give rise to the right of withdrawal, according to the valuation based on public information of Grupo Fleury Shareholders‘ Equity and Inlab audited Financial Statements made available in the due diligence.